The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

<i>XDS</i>

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463 · see citing works

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,671 · see citing works

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,791 · see citing works

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407 · see citing works

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219 · see citing works

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058 · see citing works

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,901 · see citing works

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816 · see citing works

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,778 · see citing works

Cell Death SignalingPreprint

Green, D. R., & Llambi, F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006080 · Cited by 1,117 · see citing works

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · see citing works

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 833 · see citing works

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

Delbridge, A. R. D., Grabow, S., Strasser, A., & Vaux, D. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.17 · Cited by 752 · see citing works

BCL-2 family antagonists for cancer therapy

Lessène, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 623 · see citing works

Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells

Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S.-I., Akashi, K., & Korsmeyer, S. J. (2005) · Science · doi:10.1126/science.1106114 · Cited by 573 · see citing works

Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization

Nikolovska‐Coleska, Z., Wang, R., Fang, X., Pan, H., Tomita, Y. A., Li, P., Roller, P. P., Krajewski, K., Saito, N. G., Stuckey, J. A., et al. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.05.055 · Cited by 555 · see citing works

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death &amp; Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · see citing works

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

Derenne, S., Monia, B. P., Dean, N. M., Taylor, J. K., Rapp, M.-J., Harousseau, J., Bataille, R., & Amiot, M. (2002) · Blood · doi:10.1182/blood.v100.1.194 · Cited by 429 · see citing works

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaPreprint

Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A. H., Fairlie, W. D., Izon, D. J., Zuber, J. A., Rappaport, A., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 427 · see citing works

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies

Petros, A. M., Nettesheim, D. G., Wang, Y., Olejniczak, E. T., Meadows, R. P., Mack, J. C., Swift, K. M., Matayoshi, E. D., Zhang, H., Thompson, C. B., et al. (2000) · Protein Science · doi:10.1110/ps.9.12.2528 · Cited by 413 · see citing works

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration

Perciavalle, R. M., Stewart, D. P., Koss, B. S., Lynch, J., Milasta, S., Bathina, M., Temirov, J. P., Harwig, M. C., Pelletier, S. W., Schuetz, J. D., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2488 · Cited by 407 · see citing works

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

Aubrey, B. J., Kelly, G. L., Kueh, A. J., Brennan, M. S., O’Connor, L., Milla, L., Wilcox, S., Tai, L., Strasser, A., & Herold, M. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.02.002 · Cited by 384 · see citing works

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377 · see citing works

Myeloid cell factor–1 is a critical survival factor for multiple myeloma

Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 368 · see citing works

Mcl-1 is a potential therapeutic target in multiple types of cancer

Akgül, C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329 · see citing works

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

Touzeau, C., Dousset, C., Gouill, S. L., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat‐Deceunynck, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 290 · see citing works

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunctionPreprint

Wang, X., Bathina, M., Lynch, J., Koss, B. S., Calabrese, C. R., Frase, S., Schuetz, J. D., Rehg, J. E., & Opferman, J. T. (2013) · Genes & Development · doi:10.1101/gad.215855.113 · Cited by 284 · see citing works

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failurePreprint

Thomas, R. L., Roberts, D. J., Kubli, D. A., Lee, Y., Quinsay, M. N., Owens, J. B., Fischer, K. M., Sussman, M. A., Miyamoto, S., & Gustafsson, Å. B. (2013) · Genes & Development · doi:10.1101/gad.215871.113 · Cited by 268 · see citing works

Decoding and unlocking the BCL-2 dependency of cancer cells

Juin, P. P., Geneste, O., Gautier, F., Depil, S., & Campone, M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3538 · Cited by 231 · see citing works

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

Cragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207 · see citing works

Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

Cragg, M. S., Harris, C., Strasser, A., & Scott, C. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2615 · Cited by 185 · see citing works

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

Wei, G., Margolin, A. A., Haery, L., Brown, E., Cucolo, L., Julian, B., Shehata, S., Kung, A. L., Beroukhim, R., & Golub, T. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.028 · Cited by 185 · see citing works

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

Lee, E. F., Czabotar, P. E., van Delft, M. F., Michalak, E. M., Boyle, M. J., Willis, S. N., Puthalakath, H., Bouillet, P., Colman, P. M., Huang, D. C. S., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708096 · Cited by 172 · see citing works

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Preprint

Kelly, G. L., Grabow, S., Glaser, S. P., Fitzsimmons, L., Aubrey, B. J., Okamoto, T., Valente, L. J., Robati, M., Tai, L., Fairlie, W. D., et al. (2014) · Genes & Development · doi:10.1101/gad.232009.113 · Cited by 166 · see citing works

Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164 · see citing works

Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity

Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164 · see citing works

Discovery of 2-Indole-acylsulfonamide Myeloid Cell Leukemia 1 (Mcl-1) Inhibitors Using Fragment-Based Methods

Pelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 158 · see citing works

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

Gong, J.-N., Khong, T. T., Segal, D., Yao, Y., Riffkin, C. D., Garnier, J.-M., Khaw, S. L., Lessène, G., Spencer, A. G., Herold, M. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-704908 · Cited by 150 · see citing works

A synergistic approach to protein crystallization: Combination of a fixed‐arm carrier with surface entropy reduction

Moon, A. F., Mueller, G. A., Zhong, X., & Pedersen, L. C. (2010) · Protein Science · doi:10.1002/pro.368 · Cited by 137 · see citing works

Copulatory wounding and traumatic insemination.Preprint

Reinhardt, K., Anthes, N., & Lange, R. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a017582 · Cited by 121 · see citing works

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xiao, Y., Nimmer, P. M., Sheppard, G. S., Bruncko, M., Hessler, P., Lu, X. L., Roberts-Rapp, L. A., Pappano, W. N., Elmore, S. W., Souers, A. J., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0928 · Cited by 120 · see citing works

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia

Koss, B. S., Morrison, J. B., Perciavalle, R. M., Singh, H., Rehg, J. E., Williams, R. T., & Opferman, J. T. (2013) · Blood · doi:10.1182/blood-2012-06-440230 · Cited by 93 · see citing works

Off-Rate Screening (ORS) By Surface Plasmon Resonance. An Efficient Method to Kinetically Sample Hit to Lead Chemical Space from Unpurified Reaction Products

Murray, J. B., Roughley, S. D., Matassova, N., & Brough, P. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401848a · Cited by 82 · see citing works

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520

Tunquist, B. J., Woessner, R. D., & Walker, D. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0033 · Cited by 70 · see citing works

Fragment Screening by Weak Affinity Chromatography: Comparison with Established Techniques for Screening against HSP90

Meiby, E., Simmonite, H., Strat, L. L., Davis, B. J., Matassova, N., Moore, J. D., Mrosek, M., Murray, J. B., Hubbard, R. E., & Ohlson, S. (2013) · Analytical Chemistry · doi:10.1021/ac400715t · Cited by 60 · see citing works

MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice

Grabow, S., Delbridge, A. R. D., Valente, L. J., & Strasser, A. (2014) · Blood · doi:10.1182/blood-2014-09-601567 · Cited by 44 · see citing works

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance

Spinner, S., Crispatzu, G., Yi, J.-H., Munkhbaatar, E., Mayer, P., Höckendorf, U., Müller, N., Li, Z., Schader, T., Bendz, H., et al. (2016) · Leukemia · doi:10.1038/leu.2016.49 · Cited by 32 · see citing works

Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)

Fang, C., D’Souza, B., Thompson, C. F., Clifton, M. C., Fairman, J. W., Fulroth, B., Leed, A., McCarren, P. R., Wang, L., Wang, Y., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500388q · Cited by 25 · see citing works

Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy

Nhu, D., Lessène, G., Huang, D. C. S., & Burns, C. J. (2016) · MedChemComm · doi:10.1039/c5md00582e · Cited by 16 · see citing works

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis

Lazareth, A., Song, X.-Y., Coquin, A.-S., Harel, S., Karlin, L., Belhadj, K., Roos‐Weil, D., Frenzel, L., Tamburini, J., Macro, M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.127001 · Cited by 8 · see citing works

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death &amp; Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

Targeting apoptosis in cancer therapy

Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,594 · see citing works

BCL-2 family proteins: changing partners in the dance towards death

Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574 · see citing works

BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis

McArthur, K., Whitehead, L. W., Heddleston, J. M., Li, L., Padman, B. S., Oorschot, V., Geoghegan, N. D., Chappaz, S., Davidson, S., San Chin, H., et al. (2018) · Science · doi:10.1126/science.aao6047 · Cited by 1,072 · see citing works

Emerging connectivity of programmed cell death pathways and its physiological implications

Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 986 · see citing works

Drugging the ‘undruggable’ cancer targets

Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927 · see citing works

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.253 · Cited by 903 · see citing works

Mechanisms of BCL-2 family proteins in mitochondrial apoptosis

Czabotar, P. E., & García‐Sáez, A. J. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00629-4 · Cited by 718 · see citing works

BCL-2 family isoforms in apoptosis and cancer

Warren, C., Wong‐Brown, M. W., & Bowden, N. A. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1407-6 · Cited by 697 · see citing works

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688 · see citing works

Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis

Riley, J. S., Quarato, G., Cloix, C., Lopez, J., O'Prey, J., Pearson, M., Chapman, J., Sesaki, H., Carlin, L. M., Passos, J. F., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899238 · Cited by 551 · see citing works

Targeting BCL-2 regulated apoptosis in cancer

Campbell, K. J., & Tait, S. W. G. (2018) · Open Biology · doi:10.1098/rsob.180002 · Cited by 546 · see citing works

The BCL-2 arbiters of apoptosis and their growing role as cancer targets

Adams, J. M., & Cory, S. (2018) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530 · see citing works

BCL-2 protein family: attractive targets for cancer therapy

Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2022) · APOPTOSIS · doi:10.1007/s10495-022-01780-7 · Cited by 528 · see citing works

Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2

Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G. C., Kuchel, N. W., Grohmann, C., Shibata, Y., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2020106275 · Cited by 500 · see citing works

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Tron, A. E., Belmonte, M. A., Adam, A., Aquila, B. M., Boise, L., Chiarparin, E., Cidado, J. R., Embrey, K. J., Gangl, E. T., Gibbons, F. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07551-w · Cited by 498 · see citing works

The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

Vogler, M., Braun, Y., Smith, V. M., Westhoff, M., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 448 · see citing works

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432 · see citing works

Extrinsic and intrinsic apoptosis activate pannexin‐1 to drive NLRP3 inflammasome assembly

Chen, K. W., Demarco, B., Heilig, R., Shkarina, K., Boettcher, A., Farady, C. J., Pelczar, P., & Brož, P. (2019) · The EMBO Journal · doi:10.15252/embj.2019101638 · Cited by 389 · see citing works

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 385 · see citing works

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Nechiporuk, T., Kurtz, S. E., Nikolova, O. H., Liu, T., Jones, C. L., D’Alessandro, A., Culp‐Hill, R., d’Almeida, A., Joshi, S. K., Rosenberg, M. W., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0125 · Cited by 374 · see citing works

Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity

Snyder, A. G., Hubbard, N., Messmer, M. N., Kofman, S. B., Hagan, C. E., Orozco, S. L., Chiang, K., Daniels, B. P., Baker, D. A., & Oberst, A. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw2004 · Cited by 372 · see citing works

Cell Death in the Origin and Treatment of Cancer

Strasser, A., & Vaux, D. L. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.014 · Cited by 370 · see citing works

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

Short, N. J., Konopleva, M. Y., Kadia, T. M., Borthakur, G. M., Ravandi, F., Dinardo, C. D., & Daver, N. G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 369 · see citing works

Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality

Ishizawa, J., Zarabi, S. F., Davis, R. E., Halgas, O., Nii, T., Jitkova, Y., Zhao, R., St‐Germain, J. R., Heese, L. E., Egan, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.014 · Cited by 362 · see citing works

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.005 · Cited by 361 · see citing works

Apoptotic cell death in disease—Current understanding of the NCCD 2023

Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 359 · see citing works

Anti-apoptotic BCL-2 family members in development

Opferman, J. T., & Kothari, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.170 · Cited by 349 · see citing works

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessène, G., Strasser, A., & Kelly, G. L. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 343 · see citing works

Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia

Wang, E., Lu, S. X., Pastore, A., Chen, X., Imig, J., Chun-Wei Lee, S., Hockemeyer, K., Ghebrechristos, Y. E., Yoshimi, A., Inoue, D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.010 · Cited by 338 · see citing works

Cell death pathways: intricate connections and disease implications

Kist, M., & Vucic, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106700 · Cited by 328 · see citing works

Why do BCL-2 inhibitors work and where should we use them in the clinic?

Montero, J., & Letai, A. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.183 · Cited by 325 · see citing works

Massively parallel assessment of human variants with base editor screens

Hanna, R. E., Hegde, M., Fagre, C. R., DeWeirdt, P. C., Sangree, A. K., Szegletes, Z., Griffith, A., Feeley, M. N., Sanson, K. R., Baidi, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.012 · Cited by 316 · see citing works

Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells

Stevens, B. M., Jones, C. L., Pollyea, D. A., Culp‐Hill, R., D’Alessandro, A., Winters, A. C., Krug, A., Abbott, D., Goosman, M., Pei, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00126-z · Cited by 312 · see citing works

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 313 · see citing works

Pathways and mechanisms of venetoclax resistance

Bose, P., Gandhi, V. V., & Konopleva, M. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302 · see citing works

AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

Cidado, J. R., Boiko, S., Proia, T. A., Ferguson, D., Criscione, S. W., Martin, M. S., Pop-Damkov, P., Su, N., Franklin, V. N. R., Chilamakuri, C. S. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1853 · Cited by 294 · see citing works

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

Mérino, D., Kelly, G. L., Lessène, G., Wei, A. H., Roberts, A. W., & Strasser, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.004 · Cited by 284 · see citing works

Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens

Najm, F. J., Strand, C., Donovan, K. F., Hegde, M., Sanson, K. R., Vaimberg, E. W., Sullender, M. E., Hartenian, E., Kalani, Z., Fusi, N., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4048 · Cited by 279 · see citing works

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Moreau, P., Chanan-Khan, A. A., Roberts, A. W., Agarwal, A. B., Facon, T. T. F., Kumar, S. K., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W. P., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 273 · see citing works

Sublethal cytochrome c release generates drug-tolerant persister cells

Kalkavan, H., Chen, J., Crawford, J. C., Quarato, G., FITZGERALD, P. J., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 267 · see citing works

Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance

Kapoor, I., Bodo, J., Hill, B. T., Hsi, E. D., & Almasan, A. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03144-y · Cited by 249 · see citing works

The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1β Activation

Vince, J. E., Nardo, D. D., Gao, W., Vince, A. J., Hall, C. M., McArthur, K., Simpson, D. S., Vijayaraj, S. L., Lindqvist, L., Bouillet, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.103 · Cited by 234 · see citing works

Inflammation mobilizes copper metabolism to promote colon tumorigenesis via an IL-17-STEAP4-XIAP axis

Liao, Y., Zhao, J., Bulek, K., Tang, F., Chen, X., Cai, G., Jia, S., Fox, P. L., Huang, E. H., Pizarro, T. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14698-y · Cited by 231 · see citing works

The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation

Birkinshaw, R. W., & Czabotar, P. E. (2017) · Seminars in Cell &amp; Developmental Biology · doi:10.1016/j.semcdb.2017.04.001 · Cited by 229 · see citing works

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy

Carter, J. L., Hege-Hurrish, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H. J., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 223 · see citing works

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Wei, A. H., Roberts, A. W., Spencer, A. G., Rosenberg, A. S., Siegel, D. S. D., Walter, R. B., Caenepeel, S. R., Hughes, P. E., McIver, Z., Mezzi, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100672 · Cited by 212 · see citing works

MCL-1 is a prognostic indicator and drug target in breast cancer

Campbell, K. J., Dhayade, S., Ferrari, N., Sims, A. H., Johnson, E. R., Mason, S. M., Dickson, A., Ryan, K. M., Kalna, G., Edwards, J., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0035-2 · Cited by 203 · see citing works

BCL2 and MCL1 inhibitors for hematologic malignancies

Roberts, A. W., Wei, A. H., & Huang, D. C. S. (2021) · Blood · doi:10.1182/blood.2020006785 · Cited by 203 · see citing works

Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer

López, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Román, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 203 · see citing works

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Zhang, Q., Riley-Gillis, B. M., Han, L., Jia, Y., Lodi, A., Zhang, H., Ganesan, S., Pan, R. A., Konoplev, S. N., Sweeney, S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00870-3 · Cited by 202 · see citing works

Apoptosis in Cancer Biology and Therapy

Moyer, A. F., Tanaka, K., & Cheng, E. H. Y. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-115023 · Cited by 202 · see citing works

VDAC2 enables BAX to mediate apoptosis and limit tumor development

Chin, H. S., Li, M. X., Tan, I. K. L., Ninnis, R. L., Reljic, B., Scicluna, K., Dagley, L. F., Sandow, J. J., Kelly, G. L., Samson, A. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07309-4 · Cited by 196 · see citing works

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival

Lee, E. F., Harris, T. J., Tran, S. H., Evangelista, M., Arulananda, S., John, T., Ramnac, C., Hobbs, C., Zhu, H., Gunasingh, G. P., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1568-3 · Cited by 188 · see citing works

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Bhatt, S., Pioso, M. S., Olesinski, E. A., Yilma, B., Ryan, J. A., Mashaka, T., Buon, L., Adamia, S., Zhu, H., Kuang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.10.010 · Cited by 187 · see citing works

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Mérino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 186 · see citing works

Emerging molecular therapeutic targets for cholangiocarcinoma

Ilyas, S. I., & Gores, G. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.026 · Cited by 180 · see citing works

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J. M., Rijal, S., MacRaild, S., Zhang, L., Teh, T., Tiong, I. S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0261-3 · Cited by 171 · see citing works

MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents

Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01007-9 · Cited by 171 · see citing works

The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy

Basu, A. (2022) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2021.107943 · Cited by 171 · see citing works

Control of cell death and mitochondrial fission by ERK 1/2 MAP kinase signalling

Cook, S. J., Stuart, K., Gilley, R., & Sale, M. J. (2017) · FEBS Journal · doi:10.1111/febs.14122 · Cited by 170 · see citing works

Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance

Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 170 · see citing works

A delicate balance – The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics

Knight, T. E., Luedtke, D. A., Edwards, H. J., Taub, J. W., & Ge, Y. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.01.015 · Cited by 166 · see citing works

Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma

Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 165 · see citing works

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 163 · see citing works

The multiple mechanisms of MCL1 in the regulation of cell fate

Widden, H., & Placzek, W. J. (2021) · Communications Biology · doi:10.1038/s42003-021-02564-6 · Cited by 162 · see citing works

Direct Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia

Reyna, D. E., Garner, T. P., López, A., Kopp, F., Choudhary, G. S., Sridharan, A., Narayanagari, S.-R., Mitchell, K., Dong, B., Bartholdy, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.001 · Cited by 161 · see citing works

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

Teh, T.-C., Nguyen, N.-Y., Moujalled, D. M., Segal, D., Pomilio, G., Rijal, S., Jabbour, A. M., Cummins, K. D., Lackovic, K., Blombery, P. A., et al. (2017) · Leukemia · doi:10.1038/leu.2017.243 · Cited by 161 · see citing works

The rise of apoptosis: targeting apoptosis in hematologic malignancies

Valentin, R., Grabow, S., & Davids, M. S. (2018) · Blood · doi:10.1182/blood-2018-02-791350 · Cited by 159 · see citing works

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00376-1 · Cited by 159 · see citing works

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27210-x · Cited by 158 · see citing works

Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo

Carrington, E. M., Zhan, Y., Brady, J. L., Zhang, J., Sutherland, R. M., Anstee, N. S., Schenk, R. L., Vikstrom, I. B., Delconte, R. B., Segal, D., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.30 · Cited by 157 · see citing works

MCL-1 inhibition in cancer treatment

Xiang, W., Yang, C., & Bai, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s146228 · Cited by 157 · see citing works

Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 156 · see citing works

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models

Minzel, W., Venkatachalam, A., Fink, A., Hung, E., Brachya, G., Burstain, I., Shaham, M., Rivlin, A., Omer, I., Zinger, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.045 · Cited by 155 · see citing works

Chromosome 1q21 abnormalities in multiple myeloma

Schmidt, T. M., Fonseca, R., & Usmani, S. Z. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00474-8 · Cited by 154 · see citing works

A first-generation pediatric cancer dependency map

Dharia, N. V., Kugener, G., Guenther, L. M., Malone, C. F., Durbin, A. D., Hong, A. L., Howard, T. P., Bandopadhayay, P., Wechsler, C. S., Fung, I., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00819-w · Cited by 153 · see citing works

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

Roberts, A. W., & Huang, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.553 · Cited by 153 · see citing works

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Wang, X., Ni, D., Liu, Y., & Lu, S. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.682675 · Cited by 153 · see citing works

Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer

D’Aguanno, S., & Bufalo, D. D. (2020) · Cells · doi:10.3390/cells9051287 · Cited by 152 · see citing works

Quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells

Sundaram, M. K., Raina, R., Afroze, N., Bajbouj, K., Hamad, M. A., Haque, S., & Hussain, A. (2019) · Bioscience Reports · doi:10.1042/bsr20190720 · Cited by 150 · see citing works

Recent advances in the development of Mcl-1 inhibitors for cancer therapy

Hird, A. W., & Tron, A. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.007 · Cited by 149 · see citing works

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors

Zhang, S., Zhang, M., Jing, Y., Yin, X., Ma, P., Zhang, Z., Wang, X., Di, W. J., & Zhuang, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02693-9 · Cited by 146 · see citing works

Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells

Tong, J., Wang, P., Tan, S., Chen, D., Nikolovska‐Coleska, Z., Zou, F., Yu, J., & Zhang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3242 · Cited by 143 · see citing works

BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis

Huang, K., O’Neill, K. L., Li, J., Zhou, W., Han, N., Pang, X., Wu, W., Struble, L. R., Borgstahl, G., Liu, Z., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0231-y · Cited by 140 · see citing works

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

Mali, R. S., Zhang, Q., DeFilippis, R., Cavazos, A., Kuruvilla, V. M., Raman, J., Mody, V., Choo, E. F., Dail, M., Shah, N. P., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.244020 · Cited by 140 · see citing works

Targeting Bcl-2 for the treatment of multiple myeloma

Touzeau, C., Maciag, P., Amiot, M., & Moreau, P. (2018) · Leukemia · doi:10.1038/s41375-018-0223-9 · Cited by 137 · see citing works

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Thijssen, R., Diepstraten, S. T., Moujalled, D. M., Chew, E., Flensburg, C., Shi, M. X., Dengler, M. A., Litalien, V., MacRaild, S., Chen, M., et al. (2021) · Blood · doi:10.1182/blood.2020010167 · Cited by 135 · see citing works

Genetic screens in isogenic mammalian cell lines without single cell cloning

DeWeirdt, P. C., Sangree, A. K., Hanna, R. E., Sanson, K. R., Hegde, M., Strand, C., Persky, N. S., & Doench, J. G. (2020) · Nature Communications · doi:10.1038/s41467-020-14620-6 · Cited by 133 · see citing works

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells

Li, Z., He, S., & Look, A. T. (2018) · Leukemia · doi:10.1038/s41375-018-0201-2 · Cited by 132 · see citing works

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy

Ramesh, P., & Medema, J. P. (2020) · APOPTOSIS · doi:10.1007/s10495-020-01601-9 · Cited by 131 · see citing works

BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer

Shahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 131 · see citing works

Single-cell transcriptomics identifies Mcl-1 as a target for senolytic therapy in cancer

Troiani, M., Colucci, M., D’Ambrosio, M., Guccini, I., Pasquini, E., Varesi, A., Valdata, A., Mosole, S., Revandkar, A., Attanasio, G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29824-1 · Cited by 129 · see citing works

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., et al. (2022) · Blood · doi:10.1182/blood.2021014304 · Cited by 128 · see citing works

Understanding cell cycle and cell death regulation provides novel weapons against human diseases

Wiman, K. G., & Zhivotovsky, B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12609 · Cited by 127 · see citing works

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Wei, A. H., & Tiong, I. S. (2017) · Blood · doi:10.1182/blood-2017-08-784066 · Cited by 127 · see citing works

One-Pot Synthesis of Novel Thiazoles as Potential Anti-Cancer Agents

Sayed, A. R., Gomha, S. M., Taher, E. A., Muhammad, Z. A., El-Seedi, H. R., Gaber, H. M., & Ahmed, M. M. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s221263 · Cited by 127 · see citing works

Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax

Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126 · see citing works

Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and re-sensitizes acute myeloid leukemia to BCL-2 inhibition

Carter, B. Z., Mak, P. Y., Tao, W., Warmoes, M. O., Lorenzi, P. L., Mak, D. H. F., Ruvolo, V. R., Tan, L., Cidado, J. R., Drew, L., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.260331 · Cited by 126 · see citing works

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15 · see citing works

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1 · see citing works

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 313 · see citing works

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9 · see citing works